Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 2/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11393302 | 0.99 | SIGMAR1 (0.54) | CHRM2CHRM1CHRM3SIGMAR1HTR1D | |
| SCHEMBL8677765 | 0.99 | SIGMAR1 (0.54) | CHRM2CHRM1CHRM3SIGMAR1HTR1D | |
| Hydrochloric Acid SCHEMBL7935858 | 0.97 | SIGMAR1 (0.53) | CHRM2CHRM1CHRM3SIGMAR1HTR1D | |
| Hydrochloric Acid SCHEMBL7933015 | 0.97 | SIGMAR1 (0.53) | CHRM2CHRM1CHRM3SIGMAR1HTR1D | |
| SCHEMBL9727207 | 0.97 | CHRM2 (0.55) | CHRM2CHRM1CHRM3SIGMAR1MTNR1A | |
| SCHEMBL9239027 | 0.90 | DRD2 (0.54) | CHRM2CHRM1CHRM3SIGMAR1DRD2 | |
| Hydrochloric Acid SCHEMBL9242362 | 0.89 | DRD2 (0.52) | CHRM2CHRM1CHRM3SIGMAR1DRD2 | |
| Hydrochloric Acid SCHEMBL9243515 | 0.89 | DRD2 (0.52) | CHRM2CHRM1CHRM3SIGMAR1DRD2 | |
| SCHEMBL8674841 | 0.89 | CHRM2 (0.56) | CHRM2CHRM1CHRM3SIGMAR1MTNR1A | |
| Hydrochloric Acid SCHEMBL7932854 | 0.87 | CHRM2 (0.55) | CHRM2CHRM1CHRM3SIGMAR1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-1888517-A1 | NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006126939-A1 | NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | HTR6, HTR1A, HTR1D | CHRM2 49/4885CHRM1 67/4885CHRM3 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.